A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

A Double-Blind, Randomized, Vehicle-Controlled Dose Ranging Study of the Effect of INCB018424 Phosphate Cream When Applied to Patients With Plaque Psoriasis

The study was double-blind, randomized, vehicle-controlled study with application of Ruxolitinib phosphate cream or vehicle cream in participants with stable plaque psoriasis applied once daily for 12 weeks without occlusive dressings. There were 4 treatment groups anticipated to have 50 participants in each.

Inclusion Criteria:

• Plaque psoriasis involving up to 2 to 20% Body Surface Area

Exclusion Criteria:

• Lesions solely involving intertriginous areas, the scalp or the face
• Systemic therapy for their psoriasis
• Pustular psoriasis or erythroderma
• Currently on other topical agents or Ultraviolet B (UVB) therapy within 2 weeks of the first dose of study medication
• Started or discontinued therapy within 2 months of Screening with agents that can exacerbate psoriasis
• Receiving systemic triazole antifungals except fluconazole